People on weight-loss drugs report fingernails falling off as researchers uncover surprising link

People taking GLP-1 medications for obesity or diabetes experience nail detachment and hair loss at significantly higher rates than people with similar overall health who do not take GLP-1s.

That's according to research presented Oct.

1 at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria.

Two studies evaluated 575 users of GLP-1 (glucagon-like peptide-1) drugs and a control group of 1,329 non-users, all of whom had type 2 diabetes , obesity or both.

Participants were recruited across France, the U.S, Brazil and Mexico.

POPULAR WEIGHT-LOSS DRUGS FACE NUMEROUS LAWSUITS OVER RARE ‘EYE STROKE’ LINKED TO VISION LOSS In the primary study examining nail health, 39% of GLP-1 users reported nail detachment compared with 9% of non-users.

Discoloration of the nails affected 46% of GLP-1 users versus 17% in the control group.

Overall, two-thirds of GLP-1 users (66%) reported experiencing at least one nail disorder, compared with 53% of the control group.

Researchers found that weight loss alone did not explain the difference.

Even when researchers looked only at people who lost weight, those taking GLP-1s were still more likely to have these problems.

After adjusting for existing dermatological conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more frequent among the medication group .

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," study author Dr.

Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris, said in a press release.

"Our findings show a clear association, but they also underline an important point: Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself." POPULAR GLP-1 WEIGHT-LOSS DRUGS LINKED TO POTENTIALLY DEADLY BRAIN DISORDER In another study evaluating hair and scalp conditions among the same group of participants, 50% of GLP-1 users reported unusual hair loss compared with 34% of the control group.